Merck KGaA Investor Presentation — March 2018

Document content

Stefan Oschmann, CEO

March 8, 2018Merck FY 2017 resultsPERFORMANCE AMID

HEADWINDS2Disclaimer

Cautionary Note Regarding Forward -Looking Statements andfinancial indicators

This communication may include “forward -looking statements .”Statements thatinclude words such as“anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,”

“believe,” “will,” andother words ofsimilar meaning inconnection withfuture events orfuture operating orfinancial performance areoften used toidentify forward -looking statements .All

statements inthiscommunication, other thanthose relating tohistorical information orcurrent conditions, areforward -looking statements .Weintend these forward -looking statements to

becovered bythesafeharbor provisions forforward -looking statements inthePrivate Securities Litigation Reform Actof1995.These forward -looking statements aresubject toanumber

ofrisks anduncertainties, many ofwhich arebeyond control ofMerck KGaA ,Darmstadt, Germany, which could cause actual results todiffer materially from such statements .

Risks anduncertainties include, butarenotlimited to:therisks ofmore restrictive regulatory requirements regarding drug pricing, reimbursement andapproval ;theriskofstricter

regulations forthemanufacture, testing andmarketing ofproducts ;theriskofdestabilization ofpolitical systems andtheestablishment oftrade barriers ;theriskofachanging marketing

environment formultiple sclerosis products intheEuropean Union ;theriskofgreater competitive pressure duetobiosimilars ;therisks ofresearch anddevelopment ;therisks of

discontinuing development projects andregulatory approval ofdeveloped medicines ;theriskofatemporary banonproducts/production facilities orofnon-registration ofproducts dueto

non-compliance withquality standards ;theriskofanimport banonproducts totheUnited States duetoanFDAwarning letter ;therisks ofdependency onsuppliers ;risks duetoproduct -